BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33973081)

  • 1. Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.
    Sangaré L; Divita A; Rehn M; McNamara M; Lowe KA
    Support Care Cancer; 2021 Nov; 29(11):6731-6740. PubMed ID: 33973081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
    Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
    Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing skin toxicities related to panitumumab.
    Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
    J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.
    Bouché O; Ben Abdelghani M; Labourey JL; Triby S; Bensadoun RJ; Jouary T; Des Guetz G
    World J Gastroenterol; 2019 Aug; 25(29):4007-4018. PubMed ID: 31413534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
    Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
    Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 11. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
    Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
    Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
    Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
    Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
    Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
    Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
    Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatologic Toxicities: A Chart Review of Clinical Management Among Patients With Metastatic Colorectal Cancer Treated With Panitumumab.
    Lowe KA; Sangaré L; Roehl KA; Jung S; Kafatos G; Garwin T
    Clin J Oncol Nurs; 2019 Apr; 23(2):157-164. PubMed ID: 30880806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
    Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
    Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
    Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
    Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.